EICHORCondition: Ovarian Cancer · High Grade Serous Adenocarcinoma of Ovary · Primary Peritoneal Carcinoma · Sponsor: OncoC4, Inc.
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cancer Treatment Centers of America, Phoenix. 403 | Goodyear, Arizona, United States | — |
| Honor Health, USOR, 406 | Phoenix, Arizona, United States | — |
| Nuvance Health System, 401 | Danbury, Connecticut, United States | — |
| Baptist MD Anderson Cancer Center, 404 | Jacksonville, Florida, United States | — |
| Sudarshan Sharma, MD. LTD. 414 | Hinsdale, Illinois, United States | — |
| Cancer Treatment Centers of America, Chicago. 410 | Zion, Illinois, United States | — |
| Northwest Cancer Centers - Dyer, IN - USOR, 422 | Dyer, Indiana, United States | — |
| Baptist Health Lexington, 407 | Lexington, Kentucky, United States | — |
| Norton Cancer Institute - St. Matthews, 416 | Louisville, Kentucky, United States | — |
| Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409 | Shreveport, Louisiana, United States | — |
| Minnesota Oncology Hematology, P. A. - USOR, 421 | Maplewood, Minnesota, United States | — |
| Center of Hope, 413 | Reno, Nevada, United States | — |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05446298